Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/160218| Title: | Palmitic and oleic acid: The Yin and Yang of fatty acids in type 2 diabetes mellitus |
| Author: | Palomer Tarridas, Francesc Xavier Pizarro Delgado, Javier Barroso Fernández, Emma Vázquez Carrera, Manuel |
| Keywords: | Àcid oleic Resistència a la insulina Inflamació Diabetis no-insulinodependent Obesitat Oleic acid Insulin resistance Inflammation Non-insulin-dependent diabetes Obesity |
| Issue Date: | 1-Mar-2018 |
| Publisher: | Elsevier Current Trends |
| Abstract: | Increased plasma non-esterified fatty acids (NEFAs) link obesity with insulin resistance and type 2 diabetes mellitus (T2DM). However, in contrast to the saturated FA (SFA) palmitic acid, the monounsaturated FA (MUFA) oleic acid elicits beneficial effects on insulin sensitivity, and the dietary palmitic acid:oleic acid ratio impacts diabetes risk in humans. Here we review recent mechanistic insights into the beneficial effects of oleic acid compared with palmitic acid on insulin resistance and T2DM, including its anti-inflammatory actions, and its capacity to inhibit endoplasmic reticulum (ER) stress, prevent attenuation of the insulin signaling pathway, and improve β cell survival. Understanding the molecular mechanisms of the antidiabetic effects of oleic acid may contribute to understanding the benefits of this FA in the prevention or delay of T2DM. |
| Note: | Versió postprint del document publicat a: https://doi.org/10.1016/j.tem.2017.11.009 |
| It is part of: | Trends in Endocrinology and Metabolism, 2018, vol. 29, num. 3, p. 178-190 |
| URI: | https://hdl.handle.net/2445/160218 |
| Related resource: | https://doi.org/10.1016/j.tem.2017.11.009 |
| ISSN: | 1043-2760 |
| Appears in Collections: | Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica) |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 676383.pdf | 3.29 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License
